Antiangiogenic effect of linomide on breast cancer VEGF transfectants

Marina Ziche, Giampietro Gasparini, Rangana Choudhuri, Roy Bicknell, Lucia Morbidelli, Astrid Parenti, Fabrizio Ledda

Research output: Contribution to journalArticle


The effect of the quinoline-3-carboxiamide Linomide was studied on angiogenesis promoted by breast carcinoma cell populations overexpressing vascular endothelial growth factor (VEGF). Quantification of the antiangiogenic effect of Linomide was obtained by monitoring neovascular growth in the rabbit cornea assay. MCF-7 breast carcinoma cells stably transfected with the cDNA encoding for VEGF121 were used to elicit a potent VEGF-dependent corneal angiogenesis. The treatment of rabbits with 100 mg/kg/day Linomide for 5 consecutive days produced a significant inhibition of angiogenesis. In vitro Linomide inhibited endothelial cell growth and migration elicited by VEGF, while the drug only partially modified endothelial cell growth induced by basic fibroblast growth factor (bFGF). We conclude that Linomide is an active drug able to inhibit VEGF dependent angiogenesis in breast carcinoma.

Original languageEnglish
Pages (from-to)253-256
Number of pages4
JournalOncology Reports
Issue number1 SUPPL.
Publication statusPublished - 1997



  • Angiogenesis
  • Breast carcinoma
  • Endothelial cells
  • Linomide
  • VEGF

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ziche, M., Gasparini, G., Choudhuri, R., Bicknell, R., Morbidelli, L., Parenti, A., & Ledda, F. (1997). Antiangiogenic effect of linomide on breast cancer VEGF transfectants. Oncology Reports, 4(1 SUPPL.), 253-256.